Comparative analysis of imaging modalities for pancreatic cancer detection: A comprehensive review of diagnostic Performance
DOI:
https://doi.org/10.14748/6fney215Keywords:
magnetic resonance imaging, endoscopic ultrasound, computed tomography, positron emission tomography, diagnostic, pancreatic cancerAbstract
Introduction: Pancreatic cancer continues to pose a significant clinical challenge due to its typically late diagnosis and associated poor survival outcomes. While various imaging techniques are currently employed for tumor identification and staging, a thorough comparison of their diagnostic performance is essential to enhance clinical decision-making.
Methods: This comprehensive review analyzes the diagnostic performance of major imaging modalities for pancreatic cancer detection, including computed tomography (CT), magnetic resonance imaging (MRI), endoscopic ultrasound (EUS), positron emission tomography (PET/CT), and conventional ultrasonography. Performance metrics, including sensitivity, specificity, and diagnostic accuracy, were extracted from recent meta-analyses and comparative studies.
Results: Meta-analytic data reveals MRI achieves the highest sensitivity (93%) and diagnostic accuracy (90%) for pancreatic cancer detection, followed closely by CT with 90% sensitivity and 89% diagnostic accuracy. Endoscopic ultrasound with advanced techniques demonstrates exceptional performance with 97.5% sensitivity and 93.7% accuracy, particularly for small lesions. Positron emission tomography with computed tomography shows variable performance with sensitivity ranging from 78–97% but offers unique advantages for staging and treatment monitoring. Conventional ultrasonography demonstrates high specificity (94%) but limited sensitivity (88%).
Conclusion: While multiple imaging modalities show comparable overall diagnostic performance, each offers distinct clinical advantages. MRI provides optimal primary tumor detection with superior soft tissue contrast, EUS excels in evaluating small lesions and obtaining tissue samples, CT remains the most accessible staging modality, and PET/CT offers unique metabolic information. The integration of advanced techniques including dual-energy CT and diffusion-weighted MRI may further improve detection of challenging cases. A multimodal approach tailored to individual patient characteristics and clinical scenarios optimizes diagnostic accuracy and treatment planning.
References
[1] Lee ES, Lee JM. Imaging diagnosis of pancreatic cancer: A state-of-the-art review. World J Gastroenterol. 2014 Jun 28;20(24):7864–77. doi: 10.3748/wjg.v20.i24.7864. DOI: https://doi.org/10.3748/wjg.v20.i24.7864
[2] Francis IR. Role of CT in the detection and staging of pancreatic adenocarcinoma. Cancer Imaging. 2003 Oct 1;4(1):10–4. doi: 10.1102/1470-7330.2003.0026. DOI: https://doi.org/10.1102/1470-7330.2003.0026
[3] Gonzalo-Marin J, Vila JJ, Perez-Miranda M. Role of endoscopic ultrasound in the diagnosis of pancreatic cancer. World J Gastrointest Oncol. 2014 Sep 15;6(9):360–8. doi: 10.4251/wjgo.v6.i9.360. DOI: https://doi.org/10.4251/wjgo.v6.i9.360
[4] Rhee H, Park MS. The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma. Korean J Radiol. 2021 Jan 1;22(1):23–40. doi: 10.3348/kjr.2019.0862. DOI: https://doi.org/10.3348/kjr.2019.0862
[5] Farr KP, Moses D, Haghighi KS, et al. Imaging Modalities for Early Detection of Pancreatic Cancer: Current State and Future Research Opportunities. Cancers (Basel). 2022 May 21;14(10):2539. doi: 10.3390/cancers14102539. DOI: https://doi.org/10.3390/cancers14102539
[6] Ferrara N. PET/MRI biomarkers guide personalized treatment for people with pancreatic cancer, study finds [Internet]. Mayo Clinic Comprehensive Cancer Center Blog. 2022 [cited 2025 Jun 4]. Available from: https://cancerblog.mayoclinic.org/2022/01/13/pet-mri-biomarkers-guide-personalized-treatment-for-people-with-pancreatic-cancer-study-finds/
[7] Toft J, Hadden WJ, Laurence JM, et al. Imaging modalities in the diagnosis of pancreatic adenocarcinoma: A systematic review and meta-analysis of sensitivity, specificity and diagnostic accuracy. Eur J Radiol. 2017 Jul;92:17–23. doi: 10.1016/j.ejrad.2017.04.009. DOI: https://doi.org/10.1016/j.ejrad.2017.04.009
[8] Durko Ł, Barańska M, Kaczka A, et al. Ocena czułości i swoistości wybranych badań obrazowych w diagnostyce chorób trzustki. Postępy Nauk Medycznych [Internet]. 2018 Apr 4 [cited 2025 Jun 4]; Available from: https://www.czytelniamedyczna.pl/6499,the-evaluation-of-sensitivity-and-specificity-of-selected-imaging-techniques-in.html
[9] Boekestijn B, Feshtali S, Vasen H, et al. Screening for pancreatic cancer in high-risk individuals using MRI: optimization of scan techniques to detect small lesions. Fam Cancer. 2024;23(3):295–308. doi: 10.1007/s10689-024-00394-z. DOI: https://doi.org/10.1007/s10689-024-00394-z
[10] Costache MI, Costache CA, Dumitrescu CI, et al. Which is the Best Imaging Method in Pancreatic Adenocarcinoma Diagnosis and Staging - CT, MRI or EUS? Curr Health Sci J. 2017;43(2):132–6. doi: 10.12865/CHSJ.43.02.05.
[11] Ha J, Choi SH, Byun JH, et al. Meta-analysis of CT and MRI for differentiation of autoimmune pancreatitis from pancreatic adenocarcinoma. Eur Radiol. 2021 May;31(5):3427–38. doi: 10.1007/s00330-020-07416-1. DOI: https://doi.org/10.1007/s00330-020-07416-1
[12] Endoscopic Ultrasound (EUS) [Internet]. Pancreatic Cancer Action Network. [cited 2025 Jun 4]. Available from: https://pancan.org/facing-pancreatic-cancer/diagnosis/endoscopic-ultrasound-eus/
[13] Wang XY, Yang F, Jin C, et al. Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer. World J Gastroenterol. 2014 Nov 14;20(42):15580–9. doi: 10.3748/wjg.v20.i42.15580. DOI: https://doi.org/10.3748/wjg.v20.i42.15580
[14] Ferrara N. PET/MRI biomarkers guide personalized treatment for people with pancreatic cancer, study finds [Internet]. Mayo Clinic [] Comprehensive Cancer Center Blog. 2022 [cited 2025 Jun 4]. Available from: https://cancerblog.mayoclinic.org/2022/01/13/pet-mri-biomarkers-guide-personalized-treatment-for-people-with-pancreatic-cancer-study-finds/
[15] Kurita Y, Utsunomiya D, Kubota K, et al. Diagnostic Value of Contrast-Enhanced Dual-Energy Computed Tomography in the Pancreatic Parenchymal and Delayed Phases for Pancreatic Cancer. Tomography. 2024 Oct;10(10):1591–604. doi: 10.3390/tomography10100117. DOI: https://doi.org/10.3390/tomography10100117
[16] Diagnostic Imaging [Internet]. 2022 [cited 2025 Jun 4]. Can Diffusion-Weighted MRI Have an Impact in Detecting Recurrent Pancreatic Cancer? Available from: https://www.diagnosticimaging.com/view/can-diffusion-weighted-mri-have-an-impact-in-detecting-recurrent-pancreatic-cancer-
[17] Fattahi R, Balci NC, Perman WH, et al. Pancreatic diffusion-weighted imaging (DWI): Comparison between mass-forming focal pancreatitis (FP), pancreatic cancer (PC), and normal pancreas. J Magn Reson Imaging. 2009;29(2):350–6. doi: 10.1002/jmri.21651. DOI: https://doi.org/10.1002/jmri.21651
[18] De Robertis R, D’Onofrio M, Crosara S, et al. Contrast‐enhanced ultrasound of pancreatic tumours. Australas J Ultrasound Med. 2014 Aug;17(3):96–109. doi: 10.1002/j.2205-0140.2014.tb00032.x. DOI: https://doi.org/10.1002/j.2205-0140.2014.tb00032.x
[19] Kikuyama M. A Novel Diagnostic Imaging Method for the Early Detection of Pancreatic Cancer. Diagnostics. 2023 Jan;13(12):2080. doi: 10.3390/diagnostics13122080. DOI: https://doi.org/10.3390/diagnostics13122080
